EMHTF - Emerald Health Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4125
-0.0375 (-8.33%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.4500
Open0.4475
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3975 - 0.4500
52 Week Range0.3975 - 3.4900
Volume466,177
Avg. Volume253,801
Market Cap54.003M
Beta (3Y Monthly)2.47
PE Ratio (TTM)N/A
EPS (TTM)-0.1290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Emerald Health Therapeutics Announces $2.5 Million Prospectus Sale and Concurrent Secondary Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 4,385,965 units of Emerald (each, a "Unit") at a price of $0.57 per Unit for total gross proceeds of $2,500,000 (the "Offering"). Each Unit will consist of one common share of Emerald (each, a "Common Share") and one common share purchase warrant (each, a "Warrant").

  • GlobeNewswire

    Emerald Health Therapeutics Receives Organic Certification for Greenhouse and Outdoor Metro Vancouver Operation

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has received organic certification for cannabis production at its Metro Vancouver operation in British Columbia, which encompasses 156,000 square feet in two greenhouses as well as 12 acres (~500,000 square feet) of licensed outdoor cultivation area.

  • GlobeNewswire

    Emerald Health Therapeutics to Supply STENOCARE with Medical Cannabis Products for Denmark

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has signed an agreement to become a new supplier to STENOCARE A/S (“STENOCARE”) of medical cannabis for Denmark and STENOCARE’s international markets. STENOCARE and Emerald will now commence the work with the Danish Medicines Agency (“DMA”) to have Emerald’s products ready and approved for the Danish Medical Cannabis Pilot Programme. The companies are aiming for product approval for CBD oil, THC oil and CBD+THC oil.

  • GlobeNewswire

    Emerald Health Therapeutics to Participate in Cowen 2nd Annual Boston Cannabis Conference

    VANCOUVER, British Columbia, Oct. 31, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in the Cowen 2nd Annual Boston Cannabis.

  • GlobeNewswire

    Emerald Health Therapeutics Announces Internal Reorganization

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has announced an internal reorganization including the reduction of its workforce and other expenditures. It is at the same time reinforcing its commitment to new product development focused on enhancing the modulation of the body’s endocannabinoid system. “Although such decisions are difficult, we will evolve our strategy, structure, and capabilities as necessary to be able to capitalize on key trends in the changing cannabis sector,” said Dr. Avtar Dhillon, Executive Chairman of the Board and President of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Expands Adult-Use Cannabis Product Distribution to Nova Scotia

    VANCOUVER, British Columbia, Oct. 22, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has fulfilled its first shipment of premium cannabis.

  • GlobeNewswire

    Emerald Health Therapeutics’ Québec Premium Cannabis Operation Receives Sale License Amendment, Allowing Direct Sales of Branded Products

    OTCQX: EMHTF) wholly-owned production facility, Verdélite, in St. Eustache, Québec, has received from Health Canada its license amendment permitting it to sell and distribute packaged, branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers in accordance with provincial/territorial frameworks in Canada. To date, Verdélite has been packaging product under the Emerald brand.

  • GlobeNewswire

    Emerald Health Therapeutics’ Metro Vancouver Organic Cannabis Operation Receives Cultivation Expansion License for Total Growing Area in First Greenhouse

    OTCQX: EMHTF) has received from Health Canada its cultivation license amendment and has full municipal permitting for its first of two 78,000 square foot greenhouses at its organic Metro Vancouver site in British Columbia. With an additional 50,000 square feet and seven grow areas licensed for cultivation-related activities, Emerald can now begin commercial greenhouse production at this site. This second license amendment builds on the initial site license, received in June of this year, used to propagate premium organic plant stock for this site, as well as the first amendment, received in July of this year, which added 12 acres of outdoor cultivation area.

  • GlobeNewswire

    Emerald Health Therapeutics Announces Update On Pure Sunfarms Supply Agreement

    OTCQX: EMHTF) announced that it has notified Pure Sunfarms Corp. ( the “Joint Venture”), its 50%-owned joint venture, that it does not agree that Emerald has any liability under the current Supply Agreement between Emerald and the Joint Venture with respect to the Joint Venture’s recent sales of cannabis to third parties at prices below the predetermined purchase price to Emerald (the “Purchase Price”) set out in the Supply Agreement.

  • Newsfile

    Interview with Emerald Health Therapeutics - VP Bernie Hertel Talks Pure Sunfarms JV and Expanding Operations

    Toronto, Ontario--(Newsfile Corp. - October 11, 2019) - Capital 10X President Evan Veryard sits down with Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF) VP of Finance and Communications Bernie Hertel.Cannot view this video? Visit:https://capital10x.com/interview-emerald-health-therapeutics-sunfarms-jv-expanding-operations/Mr. Hertel provides an overview of Emerald Health Therapeutics; a Canadian licensed producer of cannabis products led by a team of life science professionals. He details their "defined dose" approach to developing differentiated products for medical- and adult-use customers.This ...

  • GlobeNewswire

    Emerald Health Therapeutics’ Quebec Cannabis Operation Receives License Expansion for Total Facility Area

    OTCQX: EMHTF) wholly-owned cannabis production facility, Verdélite, in St. Eustache, Quebec, has received from Health Canada a license amendment for the complete growing and processing area in its 88,000 square foot indoor facility. The additional 50,000 square feet will allow Verdélite to expand production from 4 to 21 highly-controlled-environment grow rooms and to a total of 16 processing rooms. “Verdélite is now fully built and licensed across all its growing and processing areas, and I congratulate the team for this accomplishment,” said Thierry Schmidt, President of Verdélite.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Pure Sunfarms Begins Shipping Branded Cannabis Product to British Columbia Provincial Wholesaler

    OTCQX: EMHTF), today announced its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. ("Pure Sunfarms" or "PSF"), has begun shipping branded, packaged dried cannabis products to the British Columbia Liquor Distribution Branch (“BCLDB”), which acts as the provincial wholesaler of non-medical cannabis, supplying licensed private retailers and the government-run online store and stand-alone BC Cannabis Stores. Pure Sunfarms expects its first products to soon be available to retail customers in British Columbia. Pure Sunfarms began shipping product to the Ontario provincial wholesaler, the Ontario Cannabis Retail Corporation (the "OCRC", operating as the Ontario Cannabis Store), in September.  Combined, Ontario and British Columbia comprise more than half of Canada’s population.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Pure Sunfarms Launches Branded Product Line, Introducing Eight Products for the Recreational Market, and Begins Shipping to Ontario Cannabis Store

    OTCQX: EMHTF), today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms (PSF), has formally launched its Pure Sunfarms branded products and introduced eight strains of dried cannabis flower for the Canadian recreational market. It has also begun shipping branded dried cannabis products to the Ontario Cannabis Store (“OCS”) for retail sale in Ontario.

  • GlobeNewswire

    Emerald Health Therapeutics to Participate at the Eight Capital & Cassels Brock Global Cannabis Conference

    VANCOUVER, British Columbia, Sept. 16, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), today announced that it will participate in a panel and.

  • GlobeNewswire

    Emerald Health Therapeutics Forms Partnership With HelloMD to Continue Expanding its Medical Cannabis Patient Program

    OTCQX: EMHTF), a Canadian licenced producer of medicinal and recreational cannabis products, and HelloMD, a leading online cannabis healthcare company, have announced a partnership to further streamline and enhance Emerald’s patient onboarding experience. As part of this new partnership, Emerald has integrated HelloMD's industry-leading turnkey virtual services and patient onboarding solutions into its program for medical cannabis patients.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture, Pure Sunfarms, Receives License Amendment to Supply Cannabis Products Directly to Provincial/Territorial Wholesalers and Authorized Private Retailers

    OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received from Health Canada the amendment to its license permitting it to sell and distribute packaged, Pure Sunfarms-branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers in accordance with provincial/territorial frameworks in Canada. Pure Sunfarms currently has supply agreements in place with the Ontario Cannabis Retail Corporation ( “OCRC”, operating as the Ontario Cannabis Store) and British Columbia Liquor Distribution Branch (“BCLDB”).

  • GlobeNewswire

    Emerald Health Therapeutics Announces Pure Sunfarms’ Cannabis Supply Agreement with British Columbia Liquor Distribution Branch

    OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms (PSF), has entered into a supply agreement with the British Columbia Liquor Distribution Branch (BCLDB) to supply Pure Sunfarms-branded cannabis products for the recreational market in the Province of British Columbia. Pure Sunfarms will begin shipping to the BCLDB and the Ontario Cannabis Retail Corporation (the “OCRC,” operating as the Ontario Cannabis Store) as soon as it receives its Health Canada license amendment permitting sales and distribution of packaged cannabis products directly to provincial/territorial wholesalers and authorized private retailers in accordance with the provincial/territorial framework in Canada.

  • GlobeNewswire

    Emerald Health Therapeutics Reports Second Quarter 2019 Financial Results; Sales Double Second Quarter in a Row

    Full versions of the Company’s unaudited condensed, interim consolidated financial statements and MD&A for such period can be found on SEDAR at www.sedar.com. “During the second quarter, we appointed Riaz Bandali as Chief Executive Officer, adding extensive senior operating experience to our team and in-depth insight in the life science industry.

  • GlobeNewswire

    Emerald Health Therapeutics to Present at Rodman & Renshaw 21st Annual Global Investment Conference

    VANCOUVER, British Columbia, Aug. 28, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that it will present a corporate overview.

  • GlobeNewswire

    Emerald Health Therapeutics Announces $25 Million Convertible Debenture Unit Financing

    OTCQX: EMHTF) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 2,500 secured convertible debenture units (each, a “Convertible Debenture Unit”) of the Company at a price of $10,000 per Convertible Debenture Unit (the “Issue Price”) for gross proceeds of $25,000,000 (the “Offering”). Each Convertible Debenture Unit is comprised of one 5.0% secured convertible debenture of the Company in the principal amount of $10,000 (each, a "Convertible Debenture") and 5,000 common share purchases warrants of the Company (each, a "Warrant").

  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability

    OTCQX: EMHTF) has provided preliminary, unaudited financial results for the second quarter of 2019 for its BC-based 50%-owned joint venture, Pure Sunfarms (PSF). The Company will report its complete financial results for the second quarter ended June 30, 2019, after market close on Wednesday, August 28th, 2019, and host its second quarter 2019 financial results conference call on Thursday, August 29th, 2019 at 10:30 a.m. ET.

  • GlobeNewswire

    Emerald Health Therapeutics Outlines Production and Processing Advancements

    “With the first 1.1 million square foot (25 acre) greenhouse of our Pure Sunfarms joint venture now in full production and producing material net income and the second 1.1 million square foot greenhouse being converted for operation in 2020, we are now focused on finishing construction, licensing, and operational scaling of commercial cultivation and post-harvest processing in our other facilities and with third-party service providers, and have recently had multiple accomplishments to report,” said Riaz Bandali, Chief Executive Officer of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Appoints Chief Executive Officer

    OTCQX: EMHTF) has appointed Riaz Bandali as Chief Executive Officer. Mr. Bandali has over 25 years of experience in life sciences, with expertise in global operations, strategy development, innovation cultivation, M&A, and investment management spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

  • GlobeNewswire

    Emerald Health Therapeutics’ New Organic Cannabis Operation Receives Cultivation License for Outdoor Grow Area

    OTCQX: EMHTF) has received its cultivation license from Health Canada for the 12-acre outdoor grow area at its new organic cannabis operation in Metro Vancouver, BC. The outdoor grow area is expected to be capable of producing approximately 10,000 kg of cannabis annually with multiple crops during a full growing season. With this license effective as of July 12, 2019, Emerald is positioned to deliver one harvest and a portion of the expected full production volume this year. The 12 acres (~500,000 square feet) of outdoor cultivation are part of an overall 20-acre site that includes 156,000 sq. ft. in two greenhouses.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Achieves Its Full Annualized Production Run-Rate

    OTCQX: EMHTF) 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has achieved its full production run-rate of 75,000 kilograms of dried cannabis at its 1.1 million square foot Delta 3 greenhouse in Delta, British Columbia. “Pure Sunfarms’ growing operation is setting the standard for large-scale low cost high quality cannabis production, which we believe serves as a strong indication of what the combined expertise of Emerald and Village Farms can accomplish,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald.